Last updated: 2026-09-16 17:54:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Bolt Biotherapeutics, Inc. (BOLT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.78, with a market capitalisation of $7.67M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.13 to $7.20. This page covers its latest market performance, valuation, price trends and company information.
$7.67M | |
$3.92 | |
$861.40 | |
$3.13 | |
$4.03 | |
19.90K | |
25.06K | |
-- | |
$7.20 | |
$3.13 | |
-- | |
-- |
Bolt Biotherapeutics, Inc. (BOLT) is currently trading at $3.78 as of 2026-09-16 17:52:00, down 6.10% ($0.25) from the previous close of $4.03
During today's regular trading session, BOLT has traded between $3.13 and $861.40, with a trading volume of 19.90K shares. The current price is near the lower end of today's range.
Over the past seven days, Bolt Biotherapeutics, Inc. (BOLT) moved from $3.90 to $3.78, representing a decline of 2.97% ($0.12).
The stock traded between $3.25 and $4.36 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 37.09 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 16.1%
BOLT is currently trading at $3.78, placing it 16.1% of the way from its 52-week low of $3.13 to its 52-week high of $7.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 23 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Bolt Biotherapeutics, Inc. (BOLT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.